Protagonist Therapeutics Files 8-K
Ticker: PTGX · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1377121
Sentiment: neutral
Topics: sec-filing, 8-k, financials
TL;DR
Protagonist Therapeutics filed an 8-K on Aug 6th for financial updates.
AI Summary
On August 6, 2024, Protagonist Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along with financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text excerpt.
Why It Matters
This filing indicates Protagonist Therapeutics is providing updates on its financial condition and operations to the SEC, which is standard for public companies but can signal upcoming disclosures.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, which is standard for public companies and does not inherently indicate new risks.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- August 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37852 (identifier) — Commission File Number
- 98-0505495 (identifier) — IRS Employer Identification No.
- 7707 Gateway Blvd., Suite 140 (address) — Business and Mail Address
FAQ
What is the primary purpose of this 8-K filing by Protagonist Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed or reported as of?
The report was filed as of August 6, 2024, and the date of the earliest event reported is also August 6, 2024.
In which state was Protagonist Therapeutics, Inc. incorporated?
Protagonist Therapeutics, Inc. was incorporated in Delaware.
What is the Commission File Number for Protagonist Therapeutics, Inc.?
The Commission File Number for Protagonist Therapeutics, Inc. is 001-37852.
What is the business and mailing address of Protagonist Therapeutics, Inc. as listed in the filing?
The business and mailing address listed is 7707 Gateway Blvd., Suite 140, Newark, CA 94560-1160.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-08-06 07:08:41
Key Financial Figures
- $0.00001 — h registered Common Stock, par value $0.00001 PTGX The Nasdaq Stock Market LLC
Filing Documents
- tm2419327d1_8k.htm (8-K) — 27KB
- tm2419327d1_ex99-1.htm (EX-99.1) — 79KB
- tm2419327d1_ex99-1img001.jpg (GRAPHIC) — 12KB
- 0001104659-24-086088.txt ( ) — 305KB
- ptgx-20240806.xsd (EX-101.SCH) — 3KB
- ptgx-20240806_lab.xml (EX-101.LAB) — 33KB
- ptgx-20240806_pre.xml (EX-101.PRE) — 22KB
- tm2419327d1_8k_htm.xml (XML) — 4KB
02. Results of Operations
Item 2.02. Results of Operations and Financial Condition. On August 6, 2024, Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2024. A copy of the press release titled "Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update" is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated August 6, 2024, titled "Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagonist Therapeutics, Inc. Dated: August 6, 2024 By: /s/ Asif Ali Asif Ali Chief Financial Officer